What is BioCryst Pharmaceuticals's R&D?

BioCryst Pharmaceuticals (BCRX) reported R&D of $60.32M in Q1 2026.

How has BioCryst Pharmaceuticals's R&D changed year-over-year?

BioCryst Pharmaceuticals's R&D increased by 61.8% year-over-year, from $37.27M to $60.32M.

What is the long-term trend for BioCryst Pharmaceuticals's R&D?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's R&D has grown at a -5.6% compound annual growth rate (CAGR), from $208.81M to $166.13M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

BioCryst Pharmaceuticals BCRX R&D

R&D at other companies

Ionis PharmaceuticalsIONS

$228.9M+1.6%

Ultragenyx PharmaceuticalRARE

$187M+12.7%

ANI PharmaceuticalsANIP

$10.6M+0.3%

AnaptysBio, Inc.ANAB

$33.99M-17.5%

BridgeBio PharmaBBIO

$126.64M+13.6%

PVL

Palvella TherapeuticsPVLA

$9.33M+129%

Segments

By product

See full

Compensation and related personnel costs$27.09M—

Navenibart$9.74M—

Other non-program specific and indirect costs$7.42M—

Research, discovery and preclinical programs$3.97M—

BCX17725$1.91M-22.4%

Berotralstat$1.8M-4.2%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's R&D?: BioCryst Pharmaceuticals (BCRX) reported R&D of $60.32M in Q1 2026.
How has BioCryst Pharmaceuticals's R&D changed year-over-year?: BioCryst Pharmaceuticals's R&D increased by 61.8% year-over-year, from $37.27M to $60.32M.
What is the long-term trend for BioCryst Pharmaceuticals's R&D?: Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's R&D has grown at a -5.6% compound annual growth rate (CAGR), from $208.81M to $166.13M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.